Aspirin Exacerbated Respiratory Disease Market Size

Aspirin Exacerbated Respiratory Disease Market size is poised to grow at substantial growth rate during the forecast period i.e., between 2024-2036. The growth of the market can be attributed to increased research and development activities. The aspirin exacerbated respiratory disease is characterized by chronic sinus with asthma, nasal polyps, and sensitivity to aspirin, and other non-steroidal anti-inflammatory drugs (NSAIDs). The disease is not caused by the intake of aspirin or NSAIDs, but the disease gets worse if the patients take these medicines. According to the report given by the American Academy of Allergy, Asthma & Immunology, approximately 9% of all adults with asthma have aspirin exacerbated respiratory disease. Moreover, the number of asthma patients is mushrooming worldwide. As per the data published by the World Health Organization, the number of asthma patients was 262 million in 2019. The number is estimated to grow rapidly, subsequently causing the boost in the growth of the global aspirin exacerbated respiratory disease market during the forecast period. Moreover, governments all over the world are allotting humongous budgets for the betterment of the health sector. The data released by the World Bank shows that 9.84% of the total world GDP is current health expenditure, as of 2019. The escalating health expenditure is likely to propel the global market growth during the forecast period. Moreover, clinical studies are a prominent part of drug development. The number of registered clinical trials has increased stupendously and is estimated to reach up to 410 thousand clinical studies in March 2022, which was merely around 2100 in the year 2000. Hence, rising research is likely to fuel the global aspirin exacerbated respiratory disease market growth.